計畫名稱

計畫編號

主持人

執行期間

Accountability and Outcome Measurement of Diabetes Health Promotion Organizations in Taiwan

胡啟民

107/09-111/12

Taiwan Diabetes Registry Study

胡啟民

104/07-112/12

Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

I8F-MC-GPGM

胡啟民

107/01-111/12

A 12-month, multicentre, non-interventional, prospective study to describe clinical outcomes after iGlarLixi initiation in patients with Type 2 diabetes mellitus

OBS16039

胡啟民

109/10-111/12

Behavioral intervention and home-based resistance training to increase physical activity and muscle strength in patients with type 2 Diabetes: A randomized clinical trial

MOST 110-2314-B-075-027-MY3

胡啟民

110/08-113/07

Cross-sectional evaluation on the preference of oral agent for the treatment of diabetes (sodium-glucose cotransporter 2 inhibitor, SGLT2I) vs. dipeptidyl peptidase-4 inhibitor, DPP-4I) in patients with T2DM

D1690R00082

胡啟民

110/11-112/12

A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist. COMBINE 2

NN1535-4592

胡啟民

110/04-113/05

A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy

I8H-MC-BDCY

胡啟民

111/09-115/12

邁向2030年智慧醫療大健康跨域計畫(2/2).

NSTC 111-2634-F-A49-014-

陳涵栩(共同主持人)

2022/11/1-2023/10/31;

Role of insulin-like growth factor-1 in the management of acromegaly: Relationship to cardiovascular outcomes and pituitary function.

NSTC 111-2314-B-A49-064-

陳涵栩

2022/8/1-2023/7/31;

邁向2030年智慧醫療大健康跨域計畫(1/2).

NSTC 110-2634-F-A49-005-

陳涵栩(共同主持人)

2021/11/1-2022/10/31

A 26 week double blinded, multiregional trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-diabetic drugs, in insulin naïve subjects with type 2 diabetes:

ONWARDS 3

陳涵栩

2021/6/1-2022/12/31

水溶性環氧化物水解酶在肥胖相關代謝異常之病生理功能:造血重編程與腸道菌相之角色.

MOST 109-2320-B-010 -011 -MY3

陳涵栩(共同主持人)

2020/8/1-2023/7/31

激活素 A蛋白在高濃度葡萄糖環境下對人類臍靜脈內皮細胞功能的影響

CI-111-1

郭錦松

2022/1/1-2022/12/31

唾液皮質醇於庫欣氏症診斷及追蹤角色之研究

MOST 111-2314-B-075 -040 -MY2

林亮羽

2022/8/1-2024/7/31

妊娠甲狀腺功能和相關指標與懷孕預後之研究(第二年)

 MOST 110-2314-B-075-007

黃君睿 

 2021/08/1-2022/07/31

甲狀腺疾病患者之碘指標與疾病控制和預後相關性之研究

MOST 111-2314-B-075-071-

黃君睿 

 2022/08/01-2023/07/31

針對葛瑞夫茲氏病及抗甲狀 腺藥物引發無顆粒性白血球 症進行整合性免疫套組基因 及人類白血球表面抗原基因 研究(第二年)

VN111-03

黃君睿

 2022/01/01 -2022/12/31

應用真病人與標準化病人於模擬線上問診之成效探討

MOST 111-2410-H-075 -001 -

黃加璋

2022/08/01  ~   2023/07/31

應用真病人與標準化病人於基礎臨床技能訓練課程之成效探討

MOST 109-2511-H-075 -001 -MY2

黃加璋

2020/08/01~
2022/12/31

慢性單一FXR agonists或合併mosapride治療，對於肝硬化相關免疫機能失調(CAID)時，脾及骨髓免疫細胞異常交互作用及相關血管新生/發炎的異常機轉及治療可行性的探討

MOST 108-2314-B-075 -050 -MY3

林漢傑/黃加璋

2019/08/01~
2022/07/31